openPR Logo
Press release

Hypertriglyceridemia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Ionis Pharma, 89bio, Inc., Arrowhead Pharma, Hightide Therapeutics, Eli Lilly

04-18-2024 03:54 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Hypertriglyceridemia Market to Observe Impressive Growth

The Hypertriglyceridemia Market size was valued approximately USD 2,400 million in 2022 and the report offers an in-depth understanding of the Hypertriglyceridemia, historical and forecasted epidemiology as well as the Hypertriglyceridemia market trends in the 7MM.
DelveInsight's "Hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Hypertriglyceridemia, historical and forecasted epidemiology as well as the Hypertriglyceridemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hypertriglyceridemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypertriglyceridemia Market Forecast [https://www.delveinsight.com/sample-request/hypertriglyceridemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Hypertriglyceridemia Market Report:

* The Hypertriglyceridemia market size was valued approximately USD 2,400 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In November 2023, During the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, USA, Arrowhead Pharmaceuticals presented Phase II clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3). Results from the Phase II SHASTA-2 study revealed that plozasiran led to significant reductions, including a decrease in APOC3 by 79%, triglycerides (TG) by 74%, and remnant cholesterol by 65%, while increasing high-density lipoprotein (HDL)-cholesterol (HDL-C) by 68% at 24 weeks among patients with severe hypertriglyceridemia.
* According to DelveInsight's analysis, the diagnosed prevalent cases of hypertriglyceridemia in the 7MM were estimated to be around 69,607,255 in 2022. Projections suggest that these numbers are likely to rise during the forecast period.
* In 2022, the total diagnosed prevalent cases of severe hypertriglyceridemia in the 7MM were noted to be 3,480,363. There was a notable compound annual growth rate (CAGR) observed during the study period from 2019 to 2032.
* In the European region, Germany had the largest diagnosed prevalent population of severe hypertriglyceridemia (SHTG) with 364,734 cases in 2022, followed by the UK with 278,983 cases. Conversely, Spain had the lowest diagnosed prevalent population.
* The Hypertriglyceridemia pipeline includes significant assets such as Olezarsen (ApoC-III), ARO-APOC3, Pegozafermin (BIO89-100), and others. These promising candidates, upon successful launch, are expected to drive market growth during the forecast period.
* Key Hypertriglyceridemia Companies: Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, Eli Lilly and Company, OrsoBio, Marea Therapeutics, NorthSea Therapeutics, and others
* Key Hypertriglyceridemia Therapies: Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, HTD1801, LY3875383, TLC-2716, MAR001, NST-1024, and others
* The Hypertriglyceridemia epidemiology based on gender analyzed that the severityspecific data reveal the highest number of cases were observed in moderate level of Hypertriglyceridemia
* The Hypertriglyceridemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypertriglyceridemia pipeline products will significantly revolutionize the Hypertriglyceridemia market dynamics.

Hypertriglyceridemia Overview

Hypertriglyceridemia is a condition characterized by elevated levels of triglycerides in the blood. Triglycerides are a type of fat found in the bloodstream and stored in fat cells. When levels of triglycerides are too high, it can increase the risk of various health complications, including cardiovascular disease, pancreatitis, and metabolic syndrome.

Get a Free sample for the Hypertriglyceridemia Market Forecast, Size & Share Analysis Report:

delveinsight.com/report-store/hypertriglyceridemia-market [http://delveinsight.com/report-store/hypertriglyceridemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypertriglyceridemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hypertriglyceridemia Epidemiology Segmentation:

The Hypertriglyceridemia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of Hypertriglyceridemia
* Prevalent Cases of Hypertriglyceridemia by severity
* Gender-specific Prevalence of Hypertriglyceridemia
* Diagnosed Cases of Episodic and Chronic Hypertriglyceridemia

Download the report to understand which factors are driving Hypertriglyceridemia epidemiology trends @ Hypertriglyceridemia Epidemiology Forecast [https://www.delveinsight.com/sample-request/hypertriglyceridemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypertriglyceridemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypertriglyceridemia market or expected to get launched during the study period. The analysis covers Hypertriglyceridemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hypertriglyceridemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypertriglyceridemia Therapies and Key Companies

* Olezarsen: Ionis Pharmaceuticals
* Pegozafermin (BIO89-100): 89bio, Inc.
* ARO-APOC3: Arrowhead Pharmaceuticals, Inc.
* HTD1801: Hightide Therapeutics
* LY3875383: Eli Lilly and Company
* TLC-2716: OrsoBio
* MAR001: Marea Therapeutics
* NST-1024: NorthSea Therapeutics

Discover more about therapies set to grab major Hypertriglyceridemia market share @ Hypertriglyceridemia Treatment Landscape [https://www.delveinsight.com/sample-request/hypertriglyceridemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypertriglyceridemia Market Drivers

* The increasing prevalent population and increasing episodes of primary and secondary causes worldwide are likely to cause a surge in treatment options. Consequently, the market will witness a boost in the upcoming year.

Hypertriglyceridemia Market Barriers

* Medications with better safety and effectiveness, which provide an optimum cure, are the current unmet need of the SHTG disease market.

Scope of the Hypertriglyceridemia Market Report

* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Hypertriglyceridemia Companies: Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, Eli Lilly and Company, OrsoBio, Marea Therapeutics, NorthSea Therapeutics, and others
* Key Hypertriglyceridemia Therapies: Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, HTD1801, LY3875383, TLC-2716, MAR001, NST-1024, and others
* Hypertriglyceridemia Therapeutic Assessment: Hypertriglyceridemia current marketed and Hypertriglyceridemia emerging therapies
* Hypertriglyceridemia Market Dynamics: Hypertriglyceridemia market drivers and Hypertriglyceridemia market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Hypertriglyceridemia Unmet Needs, KOL's views, Analyst's views, Hypertriglyceridemia Market Access and Reimbursement

To know more about Hypertriglyceridemia companies working in the treatment market, visit @ Hypertriglyceridemia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hypertriglyceridemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hypertriglyceridemia Market Report Introduction

2. Executive Summary for Hypertriglyceridemia

3. SWOT analysis of Hypertriglyceridemia

4. Hypertriglyceridemia Patient Share (%) Overview at a Glance

5. Hypertriglyceridemia Market Overview at a Glance

6. Hypertriglyceridemia Disease Background and Overview

7. Hypertriglyceridemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypertriglyceridemia

9. Hypertriglyceridemia Current Treatment and Medical Practices

10. Hypertriglyceridemia Unmet Needs

11. Hypertriglyceridemia Emerging Therapies

12. Hypertriglyceridemia Market Outlook

13. Country-Wise Hypertriglyceridemia Market Analysis (2019-2032)

14. Hypertriglyceridemia Market Access and Reimbursement of Therapies

15. Hypertriglyceridemia Market Drivers

16. Hypertriglyceridemia Market Barriers

17. Hypertriglyceridemia Appendix

18. Hypertriglyceridemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypertriglyceridemia-market-to-observe-impressive-growth-during-the-forecast-period-20232032-evaluates-delveinsight-ionis-pharma-89bio-inc-arrowhead-pharma-hightide-therapeutics-eli-lilly]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hypertriglyceridemia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Ionis Pharma, 89bio, Inc., Arrowhead Pharma, Hightide Therapeutics, Eli Lilly here

News-ID: 3468936 • Views:

More Releases from ABNewswire

Revolutionizing On-the-Go Jam Sessions: Anygig Guitar Unveils Innovative Designs
Revolutionizing On-the-Go Jam Sessions: Anygig Guitar Unveils Innovative Designs
In the bustling world of music, where creativity knows no bounds, musicians are constantly seeking instruments that match their nomadic lifestyle without compromising on quality. Enter Anygig Guitar, a trailblazing brand dedicated to crafting travel-friendly instruments that redefine the boundaries of portable music-making. With a diverse lineup featuring headless guitars [https://www.anygigguitar.com/], full-scale models, and everything in between, Anygig Guitar has emerged as the go-to choice for musicians on the move. "At
Schneider Electric appoints Ruben Llanes as CEO of Digital Grid
Schneider Electric appoints Ruben Llanes as CEO of Digital Grid
Schneider Electric, the leader in the digital transformation of energy management and automation, has appointed Ruben Llanes as Chief Executive Officer of Digital Grid. Digital Grid aims to accelerate grid modernization, from grid to prosumer, under the pillars of innovation, adoption and partnerships. Previously CEO of AutoGrid, Llanes delivered growth, introduced improved processes and methods, and launched new solutions, including turnkey VPPs. His tenure culminated with the sale of AutoGrid to
Celebrating Victory:
Celebrating Victory: "The Voice of Lithuania. Generations" 2nd Season Won by Boy …
Image: https://www.abnewswire.com/uploads/9756fdbda22425795f03c6a1d7cd9039.jpg This past Sunday marked the grand finale of "Lithuania's Voice. Generations" at the Kaunas "Zalgiris" Arena, a momentous event that showcased the pinnacle of talent and competition. Nine finalists vied for the coveted 15,000 cash prize and the contract with ELITAZ Music [https://elitaz.lt/], each delivering breathtaking musical and visual performances crafted in collaboration with the project team specifically for this climactic evening. Prior to the final showdown, esteemed guests gathered
Packaging Adhesives MarketApplications, Growth, Size, Opportunities, Top Players, Share, Trends, Key Segments, Regional Insights, Graph and Forecast to 2028
Packaging Adhesives MarketApplications, Growth, Size, Opportunities, Top Players …
Packaging Adhesives Market by Resin Type (Polyurethane, Acrylics, PVA), Technology (Solvent-based, Water-Based, Hot-Melt), Application (Case & Carton, Corrugated Packaging, Labeling, Flexible Packaging, Folding Cartons), and Region - Global Forecast to 2028 The packaging adhesives market [https://www.marketsandmarkets.com/Market-Reports/packaging-adhesive-market-118442967.html] exhibits good growth potential and is projected to reach a market size of USD 18.6 billion by 2028 from USD 15.3 billion in 2022, at a CAGR of 3.2%. Polyvinyl acetate (PVA) resin accounted for

All 5 Releases


More Releases for Hypertriglyceridemia

Severe Hypertriglyceridemia Pipeline Assessment - FDA, EMA, and PMDA Approvals, …
Severe Hypertriglyceridemia pipeline constitutes 10+ key companies continuously working towards developing 10+ Severe Hypertriglyceridemia treatment therapies, analyzes DelveInsight Hypertriglyceridemia refers to a fasting plasma triglyceride measurement that is increased, typically above the 95th percentile for age and sex- although additional quantitative or qualitative lipoprotein abnormalities can also be present. Patients can fluctuate between hypertriglyceridemic states: given an appropriate metabolic stress, mild or moderate hypertriglyceridemia can deteriorate into severe hypertriglyceridemia. "Severe Hypertriglyceridemia
Hypertriglyceridemia Therapeutics Market 2022 Analysis by Growth Revenue, Develo …
Coherent Market Insights provides an encyclopedic study of the Hypertriglyceridemia Therapeutics Market with holistic insights into important factors and aspects impacting the future growth of the market. The Hypertriglyceridemia Therapeutics Market has been analyzed for the forecast period 2022-2028 and the historical period 2016-2021. To help players gain a thorough understanding of the Hypertriglyceridemia Therapeutics Market and its critical dynamics, the research study provides detailed qualitative and quantitative analysis. The report
Hypertriglyceridemia-Pipeline Service Market Size 2021 by Product Sales, Revenue …
This report on The Hypertriglyceridemia-Pipeline Service Market is segmented into sections that provides information on the historical and present patient pool as well as the projected trend for each of the seven major nations. It examines various research and the perspectives of important opinion leaders to assist in identifying the reasons for present and anticipated trends. In this section of report, find the diagnosed patient pool, their patterns, and the
Hypertriglyceridemia Treatment market: How leading companies can make this smart …
The Hypertriglyceridemia Treatment Market is required to display a quickly expanding development rate during the Forecast Period.["In spite of the epidemic subverting worldwide economic situations, the Global Hypertriglyceridemia Treatment market is foreseen to report healthy CAGR in the near Future"]. A few factors, for example, global demand, technology advancements, industrialization, and urbanizations have been supporting business sector improvement throughout the most recent decade. This Hypertriglyceridemia Treatment market report work with respect
Hypertriglyceridemia Treatment Market: Global Market Size, Industry Trends, Lead …
OMR recently published new report titled "Hypertriglyceridemia Treatment Market -global trends, market share, industry size, growth, opportunities, and market forecast - 2019-2025" to its portfolio. This latest industry research study analyses the Hypertriglyceridemia TreatmentMarket by different segments, companies, and regions. Request a free sample of our report on Hypertriglyceridemia Treatment Market: https://www.orionmarketreports.com/hypertriglyceridemia-treatment-market/1345/#ert_pane1-1 Hypertriglyceridemia Treatment Market research report includes the depth analysis of each segment from 2018 to 2025 considering 2018 as the
Lipid Disorder Treatment Market Size by Drug Type (Pravastatin, Simvastatin), by …
The Lipid Disorder Treatment Market 2019 industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years. Further, justification for the estimates for each segments, and regions will also be provided in qualitative form. You can get a sample copy of this report at https://www.orianresearch.com/request-sample/1371292 Lipid disorder includes a broad range of metabolic conditions that affect lipid levels in the blood. Lipid disorders